Annual CAPEX
$107.61 M
-$23.93 M-18.19%
31 December 2023
Summary:
BioMarin Pharmaceutical annual capital expenditures is currently $107.61 million, with the most recent change of -$23.93 million (-18.19%) on 31 December 2023. During the last 3 years, it has fallen by -$29.91 million (-21.75%). BMRN annual CAPEX is now -52.73% below its all-time high of $227.65 million, reached on 31 December 2015.BMRN CAPEX Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CAPEX
$21.18 M
-$663.00 K-3.04%
30 September 2024
Summary:
BioMarin Pharmaceutical quarterly capital expenditures is currently $21.18 million, with the most recent change of -$663.00 thousand (-3.04%) on 30 September 2024. Over the past year, it has dropped by -$2.24 million (-9.58%). BMRN quarterly CAPEX is now -79.60% below its all-time high of $103.81 million, reached on 31 December 2015.BMRN Quarterly CAPEX Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CAPEX
$113.81 M
-$2.24 M-1.93%
30 September 2024
Summary:
BioMarin Pharmaceutical TTM capital expenditures is currently $113.81 million, with the most recent change of -$2.24 million (-1.93%) on 30 September 2024. Over the past year, it has increased by +$6.54 million (+6.10%). BMRN TTM CAPEX is now -50.30% below its all-time high of $229.03 million, reached on 31 March 2016.BMRN TTM CAPEX Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BMRN CAPEX Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -18.2% | -9.6% | +6.1% |
| 3 y3 years | -21.8% | +4.0% | -0.8% |
| 5 y5 years | -25.6% | -40.2% | -21.3% |
BMRN CAPEX High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -21.8% | at low | -52.3% | +4.0% | -18.4% | +6.1% |
| 5 y | 5 years | -34.1% | at low | -65.2% | +5.1% | -35.7% | +6.1% |
| alltime | all time | -52.7% | +2762.0% | -79.6% | +4335.2% | -50.3% | >+9999.0% |
BioMarin Pharmaceutical CAPEX History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $21.18 M(-3.0%) | $113.81 M(-1.9%) |
| June 2024 | - | $21.84 M(-36.0%) | $116.06 M(-0.8%) |
| Mar 2024 | - | $34.10 M(-7.1%) | $116.95 M(+8.7%) |
| Dec 2023 | $107.61 M(-18.2%) | $36.70 M(+56.7%) | $107.61 M(+0.3%) |
| Sept 2023 | - | $23.42 M(+3.0%) | $107.27 M(-10.8%) |
| June 2023 | - | $22.73 M(-8.2%) | $120.33 M(-4.2%) |
| Mar 2023 | - | $24.77 M(-31.9%) | $125.63 M(-4.5%) |
| Dec 2022 | $131.54 M(+10.3%) | $36.36 M(-0.3%) | $131.54 M(-5.7%) |
| Sept 2022 | - | $36.47 M(+30.1%) | $139.54 M(+13.1%) |
| June 2022 | - | $28.04 M(-8.6%) | $123.43 M(+1.5%) |
| Mar 2022 | - | $30.68 M(-30.8%) | $121.65 M(+2.0%) |
| Dec 2021 | $119.22 M(-13.3%) | $44.36 M(+117.9%) | $119.22 M(+3.9%) |
| Sept 2021 | - | $20.36 M(-22.4%) | $114.73 M(+0.2%) |
| June 2021 | - | $26.25 M(-7.1%) | $114.52 M(-5.9%) |
| Mar 2021 | - | $28.25 M(-29.1%) | $121.76 M(-11.5%) |
| Dec 2020 | $137.52 M(-15.8%) | $39.86 M(+97.8%) | $137.52 M(-13.2%) |
| Sept 2020 | - | $20.15 M(-39.8%) | $158.50 M(-8.8%) |
| June 2020 | - | $33.48 M(-23.9%) | $173.75 M(-1.8%) |
| Mar 2020 | - | $44.02 M(-27.7%) | $176.96 M(+8.3%) |
| Dec 2019 | $163.41 M(+13.0%) | $60.84 M(+71.8%) | $163.41 M(+13.0%) |
| Sept 2019 | - | $35.41 M(-3.5%) | $144.64 M(-9.1%) |
| June 2019 | - | $36.70 M(+20.5%) | $159.09 M(+9.8%) |
| Mar 2019 | - | $30.46 M(-27.6%) | $144.92 M(+0.2%) |
| Dec 2018 | $144.62 M(-27.4%) | $42.08 M(-15.6%) | $144.62 M(+1.5%) |
| Sept 2018 | - | $49.86 M(+121.4%) | $142.43 M(+5.5%) |
| June 2018 | - | $22.52 M(-25.3%) | $135.05 M(-15.7%) |
| Mar 2018 | - | $30.16 M(-24.4%) | $160.29 M(-19.5%) |
| Dec 2017 | $199.22 M(+34.3%) | $39.89 M(-6.1%) | $199.22 M(-5.5%) |
| Sept 2017 | - | $42.48 M(-11.0%) | $210.90 M(+8.4%) |
| June 2017 | - | $47.76 M(-30.9%) | $194.52 M(+12.9%) |
| Mar 2017 | - | $69.09 M(+34.0%) | $172.27 M(+16.1%) |
| Dec 2016 | $148.38 M(-34.8%) | $51.57 M(+97.6%) | $148.38 M(-26.0%) |
| Sept 2016 | - | $26.10 M(+2.3%) | $200.62 M(-8.4%) |
| June 2016 | - | $25.51 M(-43.6%) | $219.07 M(-4.3%) |
| Mar 2016 | - | $45.20 M(-56.5%) | $229.03 M(+0.6%) |
| Dec 2015 | $227.65 M(+94.5%) | $103.81 M(+133.0%) | $227.65 M(+50.2%) |
| Sept 2015 | - | $44.56 M(+25.7%) | $151.61 M(+14.7%) |
| June 2015 | - | $35.46 M(-19.1%) | $132.22 M(-3.7%) |
| Mar 2015 | - | $43.83 M(+57.9%) | $137.29 M(+17.3%) |
| Dec 2014 | $117.06 M(+79.6%) | $27.77 M(+10.3%) | $117.06 M(-1.7%) |
| Sept 2014 | - | $25.17 M(-37.9%) | $119.05 M(+11.2%) |
| June 2014 | - | $40.52 M(+71.6%) | $107.08 M(+39.1%) |
| Mar 2014 | - | $23.61 M(-20.7%) | $76.97 M(+18.1%) |
| Dec 2013 | $65.19 M(+46.3%) | $29.75 M(+125.4%) | $65.19 M(+32.1%) |
| Sept 2013 | - | $13.20 M(+26.8%) | $49.34 M(-3.5%) |
| June 2013 | - | $10.41 M(-12.0%) | $51.15 M(+1.8%) |
| Mar 2013 | - | $11.83 M(-14.9%) | $50.22 M(+12.7%) |
| Dec 2012 | $44.57 M(-71.1%) | $13.89 M(-7.4%) | $44.57 M(-63.0%) |
| Sept 2012 | - | $15.01 M(+58.3%) | $120.36 M(-25.6%) |
| June 2012 | - | $9.48 M(+53.5%) | $161.73 M(+4.9%) |
| Mar 2012 | - | $6.18 M(-93.1%) | $154.16 M(-0.0%) |
| Dec 2011 | $154.22 M | $89.68 M(+59.0%) | $154.22 M(+104.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2011 | - | $56.39 M(+2852.3%) | $75.28 M(+166.3%) |
| June 2011 | - | $1.91 M(-69.4%) | $28.26 M(-32.0%) |
| Mar 2011 | - | $6.24 M(-41.9%) | $41.59 M(-15.9%) |
| Dec 2010 | $49.46 M(-44.9%) | $10.74 M(+14.6%) | $49.46 M(-19.4%) |
| Sept 2010 | - | $9.37 M(-38.5%) | $61.34 M(-21.9%) |
| June 2010 | - | $15.24 M(+8.0%) | $78.53 M(-7.8%) |
| Mar 2010 | - | $14.11 M(-37.6%) | $85.17 M(-5.2%) |
| Dec 2009 | $89.80 M(+59.3%) | $22.62 M(-14.8%) | $89.80 M(+13.5%) |
| Sept 2009 | - | $26.56 M(+21.4%) | $79.10 M(+22.3%) |
| June 2009 | - | $21.88 M(+16.8%) | $64.66 M(+17.1%) |
| Mar 2009 | - | $18.74 M(+57.2%) | $55.22 M(-2.0%) |
| Dec 2008 | $56.37 M(+151.5%) | $11.92 M(-1.6%) | $56.37 M(+3.7%) |
| Sept 2008 | - | $12.11 M(-2.7%) | $54.38 M(+13.5%) |
| June 2008 | - | $12.44 M(-37.4%) | $47.92 M(+22.7%) |
| Mar 2008 | - | $19.89 M(+100.2%) | $39.07 M(+74.3%) |
| Dec 2007 | $22.41 M(-8.8%) | $9.94 M(+75.9%) | $22.41 M(+42.8%) |
| Sept 2007 | - | $5.65 M(+57.2%) | $15.69 M(+25.4%) |
| June 2007 | - | $3.59 M(+11.1%) | $12.51 M(-53.6%) |
| Mar 2007 | - | $3.23 M(+0.6%) | $26.95 M(+9.6%) |
| Dec 2006 | $24.58 M(+279.0%) | $3.22 M(+30.3%) | $24.58 M(-6.5%) |
| Sept 2006 | - | $2.47 M(-86.3%) | $26.30 M(+8.0%) |
| June 2006 | - | $18.03 M(+1974.6%) | $24.35 M(+259.5%) |
| Mar 2006 | - | $869.00 K(-82.4%) | $6.77 M(+4.4%) |
| Dec 2005 | $6.49 M(-73.1%) | $4.94 M(+864.6%) | $6.49 M(-29.7%) |
| Sept 2005 | - | $512.00 K(+13.0%) | $9.22 M(-52.6%) |
| June 2005 | - | $453.00 K(-22.2%) | $19.46 M(-16.9%) |
| Mar 2005 | - | $582.00 K(-92.4%) | $23.43 M(-2.7%) |
| Dec 2004 | $24.07 M(+302.9%) | $7.67 M(-28.6%) | $24.07 M(+22.0%) |
| Sept 2004 | - | $10.75 M(+143.1%) | $19.74 M(+81.8%) |
| June 2004 | - | $4.42 M(+258.8%) | $10.86 M(+54.3%) |
| Mar 2004 | - | $1.23 M(-63.1%) | $7.04 M(+17.8%) |
| Dec 2003 | $5.97 M(+22.9%) | $3.34 M(+79.0%) | $5.97 M(+92.0%) |
| Sept 2003 | - | $1.86 M(+209.8%) | $3.11 M(+316.6%) |
| June 2003 | - | $602.00 K(+254.1%) | $747.00 K(-73.2%) |
| Mar 2003 | - | $170.00 K(-64.2%) | $2.79 M(-42.7%) |
| Dec 2002 | $4.86 M(-72.7%) | $475.00 K(-195.0%) | $4.86 M(-57.0%) |
| Sept 2002 | - | -$500.00 K(-118.9%) | $11.30 M(-37.6%) |
| June 2002 | - | $2.64 M(+17.6%) | $18.11 M(-7.7%) |
| Mar 2002 | - | $2.25 M(-67.5%) | $19.63 M(+10.2%) |
| Dec 2001 | $17.81 M(+373.7%) | $6.91 M(+9.4%) | $17.81 M(+40.3%) |
| Sept 2001 | - | $6.32 M(+51.9%) | $12.70 M(+79.6%) |
| June 2001 | - | $4.16 M(+866.5%) | $7.07 M(+97.4%) |
| Mar 2001 | - | $430.00 K(-76.1%) | $3.58 M(-4.7%) |
| Dec 2000 | $3.76 M(-83.6%) | $1.80 M(+161.7%) | $3.76 M(-35.2%) |
| Sept 2000 | - | $687.00 K(+3.0%) | $5.81 M(-53.2%) |
| June 2000 | - | $667.00 K(+9.7%) | $12.42 M(-40.2%) |
| Mar 2000 | - | $608.00 K(-84.2%) | $20.77 M(-9.5%) |
| Dec 1999 | $22.94 M(+258.5%) | $3.84 M(-47.3%) | $22.94 M(+20.1%) |
| Sept 1999 | - | $7.30 M(-19.1%) | $19.10 M(+61.9%) |
| June 1999 | - | $9.02 M(+224.3%) | $11.80 M(+324.3%) |
| Mar 1999 | - | $2.78 M | $2.78 M |
| Dec 1998 | $6.40 M | - | - |
FAQ
- What is BioMarin Pharmaceutical annual capital expenditures?
- What is the all time high annual CAPEX for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical annual CAPEX year-on-year change?
- What is BioMarin Pharmaceutical quarterly capital expenditures?
- What is the all time high quarterly CAPEX for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical quarterly CAPEX year-on-year change?
- What is BioMarin Pharmaceutical TTM capital expenditures?
- What is the all time high TTM CAPEX for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical TTM CAPEX year-on-year change?
What is BioMarin Pharmaceutical annual capital expenditures?
The current annual CAPEX of BMRN is $107.61 M
What is the all time high annual CAPEX for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high annual capital expenditures is $227.65 M
What is BioMarin Pharmaceutical annual CAPEX year-on-year change?
Over the past year, BMRN annual capital expenditures has changed by -$23.93 M (-18.19%)
What is BioMarin Pharmaceutical quarterly capital expenditures?
The current quarterly CAPEX of BMRN is $21.18 M
What is the all time high quarterly CAPEX for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high quarterly capital expenditures is $103.81 M
What is BioMarin Pharmaceutical quarterly CAPEX year-on-year change?
Over the past year, BMRN quarterly capital expenditures has changed by -$2.24 M (-9.58%)
What is BioMarin Pharmaceutical TTM capital expenditures?
The current TTM CAPEX of BMRN is $113.81 M
What is the all time high TTM CAPEX for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high TTM capital expenditures is $229.03 M
What is BioMarin Pharmaceutical TTM CAPEX year-on-year change?
Over the past year, BMRN TTM capital expenditures has changed by +$6.54 M (+6.10%)